Don't close this page .. Test is protected .. Answers cannot be changed .. We try now to connect to save and correct your answers.
Connection trial number:
If this message persists for long, please check your internet connection.
This test is monitored
Switching to another webpage or any other program is considered a cheating behavior and your test may be automatically terminated.
Okay
Important Notice
If you moved to the next question, you will not be able to come back to this question again.
Cancel
Move to next question
Final exam لمادة موضوعات مختارة في علم الادوية
Student data
×
Student data
Student name: ***
Student number: ***
Class or section: ***
Test instructions
×
Test instructions
عدد الاسءلة هي 63 سؤال
Page direction
×
Change page direction
Right to left
Left to right
Q1
Score: 0.5
A- animal
B- human
C- in vivo
Q2
Score: 0.5
صح
خطأ
Q3
Score: 0.5
صح
خطأ
Q4
Score: 0.5
A- absorption
B- medication compliance
C- reduction in GI motility
D- Elimination
E- A+ D
F- all the above
Q5
Score: 0.5
A- sulfonamide
B- Aspirin
C- Mepiridine
D- Benzodiazepine
Q6
Score: 0.5
A- dose
B- Age
C- systemic toxicity
D- Route
Q7
Score: 0.5
صح
خطأ
Q8
Score: 0.5
صح
خطأ
Q9
Score: 0.5
A- pharmacodynamic
B- direct toxicity
C- genotoxicity
D- all the above
Q10
Score: 0.5
A- phase -1
B- phase- 2
Q11
Score: 0.5
صح
خطأ
Q12
Score: 0.5
A- factor including the vascular perfusion
B- By 6 weeks of age
C- such as penicillin
D- are reduced by 50% in premature
Q13
Score: 0.5
صح
خطأ
Q14
Score: 0.5
A- result in polar
B- water soluble
C- oxidase
D- conjugation
Q15
Score: 0.5
صح
خطأ
Q16
Score: 0.5
Q17
Score: 0.5
A- treatment of pre- existing chronic disorder
B- always use drugs which have been widely used
C- over the counter
D- drugs for medical condition prior to confirmation of pregnancy
Q18
Score: 0.5
Q19
Score: 0.5
A- chemical development
B- safety assessment
C- drug metabolism
D- all the above
Q20
Score: 0.5
صح
خطأ
Q21
Score: 0.5
A- fetal period
B- organogenesis
C- Blastogenesis
D- non the above
Q22
Score: 0.5
A- mental retardation
B- Mutagenesis
C- is seen in up to 25% of the fetuses with first - trimester exposure to coumarins
D- carcinogenesis
Q23
Score: 0.5
A- urinary retention
B- hyperglycemia
C- heart block
D- GI hemorrhage
Q24
Score: 0.5
صح
خطأ
Q25
Score: 0.5
صح
خطأ
Q26
Score: 0.5
صح
خطأ
Q27
Score: 0.5
A- albumin
B- alpha-1 acid glycoproteins
C- T cell
Q28
Score: 0.5
A- Clark's Rule
B- Youngs Rule
C- creatinine clearance
D- non the above
Q29
Score: 0.5
صح
خطأ
Q30
Score: 0.5
A- check chemical stability
B- determine major metabolite
C- optimize and scale up synthesis and purification
D- produce GMP batches are required for biological and clinical test
Q31
Score: 0.5
A- pharmaceutic interaction
B- pharmacodynamic interaction
C- pharmacokinetic interaction
Q32
Score: 0.5
A- gene
B- protein
C- cell
D- tissue
Q33
Score: 0.5
A- producing hypotension
B- producing hypoglycemia
C- producing hypertension
D- producing hyperglycemia
Q34
Score: 0.5
صح
خطأ
Q35
Score: 0.5
Q36
Score: 0.5
A- spontaneous
B- route of exposure
C- species
D- sex of test animal formulation
Q37
Score: 0.5
A- vaccination
B- blood transfusion
C- transplantation
D- drug therapy
Q38
Score: 0.5
A- Arthritis
B-metabolism
C- peptic ulcer
D- stroke
Q39
Score: 0.5
صح
خطأ
Q40
Score: 0.5
A- nasal hypoplasia
B- bone stippling on X- Ray
C- depressed bridge of nose
D- all the above
E- non the above
Q41
Score: 0.5
A- pregnancy
B- cough
C- diarrhea
D- heart
Q42
Score: 0.5
Q43
Score: 0.5
A- digoxin
B- NSAIDS
C- Atropine- like drugs
Q44
Score: 0.5
A- drugs
B- food additives
C- cosmetic
D- pesticide
E- all of the above
Q45
Score: 0.5
A- Elderly people
B- Infant
C- they are the major consumer of drug
D- include polypharmacy
Q46
Score: 0.5
A- lethal dose to assayed in the same population
B- dose required for sub- lethal toxicity
C- all the above
Q47
Score: 0.5
صح
خطأ
Q48
Score: 0.5
A- Health
B- disease
C- organization
D- non the above
Q49
Score: 0.5
Q50
Score: 0.5
Q51
Score: 0.5
A- strength of hypothesis
B- Availibility of target
C- market prediction
D- Toxicology
Q52
Score: 0.5
صح
خطأ
Q53
Score: 0.5
A- digoxin
B- TCAS
C- Atropine like drugs
Q54
Score: 0.5
A- category A
B- category B
C- category c
D- category D
E- category x
Q55
Score: 0.5
A- drug action
B- cell
B- tissue
C- system
Q56
Score: 0.5
A- phase I
B- phase II
C- phaseI and II and III and IV
D- phase III
Q57
Score: 0.5
A- Antibodies
B- vaccines
C- enzyme
D- DNA product
Q58
Score: 0.5
A- In vivo
B- in human
C- in animal
D- in vitro
Q59
Score: 0.5
A- Effect
B- Efficacy
C- Effectiveness
D- BENEFIT
Q60
Score: 0.5
A- Easily
B- with difficult
C- poorly
D- non of the above
Q61
Score: 0.5
A- poly pharmacy
B- multiple disease state
C- increase severity of illness
D- B+ C
E- all the above
Q62
Score: 0.5
A- usually placebo controlled
B- phase IIa is exploratory and phase IIb is confirmatory
C- the opproxinate number of healthy subject is 50- 500
D- gives confirmation of clinical dose and regimen for efficacy
Q63
Score: 0.5
Q64
Score: 0.5
A- structural
B- spontaneous
C- antidotal
D- route of exposure
Q65
Score: 0.5
صح
خطأ
Q66
Score: 0.5
Q67
Score: 0.5
A- mental retardation
B- Hyperactivity
C- all the above
D- non of the above
Q68
Score: 0.5
A- 5- 10 years
B- 1 month
C- 15- 25 years
D- 9 month to 3 years
Q69
Score: 0.5
صح
خطأ
Q70
Score: 0.5
A- pharmacodynamic drug- drug interaction
B- pharmacokinetic drug- drug interaction
C- pharmaceutic interaction
Q71
Score: 0.5
Q72
Score: 0.5
A- FDA
B- NMR
C- IND
Q73
Score: 0.5
صح
خطأ
Q74
Score: 0.5
A- transplant surgery
B- Apligraf
C- B cell
D- influenza
Q75
Score: 0.5
Q76
Score: 0.5
A- Aspirin
B- sulfonamide
C- chloramphenicol
D- Tetracycline
Q77
Score: 0.5
A- chemical modification of known molecule
B- biotechnology and cloning
C- random screening for biological activity of large numbers of natural
D- all the above
Q78
Score: 0.5
صح
خطأ
Q79
Score: 0.5
Q80
Score: 0.5
A- conducting a clinical trial
B- Analyzing the outcome of a clinical trial
C- Givrine permission so clinical trial
D- non the above
Questions you haven't answered yet:
Are you sure you want to end this test and send your answers?
All copy rights reserved
©
arab-exams.com
2014-2023
Dismiss this alert